Sometimes you have to stay to the end of the meeting. Shares in Gilead Sciences Inc. plunged $8, or more than 20 percent, on Friday, prompting a halt in trading, when it was disclosed that the company's drug Vistide, under review as …
Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments. Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments. Home Mail Search News Cricket …
However, Gilead Sciences just proved why you can't jump to these sorts of conclusions for this particular industry. …
Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions. Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics …
As summer starts, the bloom seems to be off the rose for Gilead. Its positive Phase III results for heart drug darusentan boosted the stock in April to $48.37, but since then it's fallen back to around $43. (That's not entirely to do with …
What's the outlook for Gilead Sciences' stock? Over the short run, that question is next to impossible to answer. Over the long run, though, investors can project how well Gilead stock (or any other stock, for that matter) should perform with …
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President …
* Gilead receives approval in Canada for expanded indication of epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV * Gilead Sciences - On September 8, 2017 co entered into a $6.0 …
New commercial DuoBody technology platform collaboration with Gilead Genmab granted Gilead an exclusive license to create a bispecific antibody with the DuoBody technology and an option to obtain a second exclusive license …
*Close price adjusted for splits.**Adjusted close price adjusted for both dividends and splits. Loading more data...